<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Souha S Kanj, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1145081030"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Pseudomonas aeruginosa</em> is an important pathogen in the differential diagnosis of several common infections. Consideration of this organism is important because it has the potential to cause severe infections, especially in immunocompromised hosts, and to be multidrug resistant.</p><p>The clinical manifestations, diagnosis, and treatment of <em>P. aeruginosa</em> eye, ear, urinary tract, gastrointestinal tract, and central nervous system infections will be reviewed here. </p><p>The general principles of antimicrobial treatment of infections caused by <em>P. aeruginosa</em>, including antibiotic options and decisions on combination therapy, are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"</a>.)</p><p>The clinical manifestations and management of other <em>P. aeruginosa</em> infections and the epidemiology and pathogenesis of infection with this organism are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3142.html" rel="external">"Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">"Pseudomonas aeruginosa pneumonia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2136.html" rel="external">"Pseudomonas aeruginosa bacteremia and endocarditis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Pseudomonas aeruginosa'</a> and  <a class="medical medical_review" href="/z/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"</a>.) </p><p></p><p class="headingAnchor" id="H2"><span class="h1">EYE INFECTIONS</span><span class="headingEndMark"> — </span><em>P. aeruginosa</em> is capable of causing both minor and vision-threatening infections of the eye. These infections include dacryocystitis, blepharoconjunctivitis, and orbital cellulitis. <em>P. aeruginosa</em> can also be directly introduced into the cornea, anterior chamber, or vitreous via trauma, surgery, or contaminated optic medications (eg, <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">artificial tears</a>) [<a href="#rid1">1</a>]. <em>P. aeruginosa</em> has been implicated in some cases of ophthalmia neonatorum and scleral abscesses. Hematogenous infection of the vitreous occurs rarely in patients with <em>P. aeruginosa</em> bacteremia. (See  <a class="medical medical_review" href="/z/d/html/3414.html" rel="external">"Orbital cellulitis"</a> and  <a class="medical medical_review" href="/z/d/html/3418.html" rel="external">"Bacterial endophthalmitis"</a> and  <a class="medical medical_review" href="/z/d/html/6907.html" rel="external">"Conjunctivitis", section on 'Bacterial conjunctivitis'</a>.)</p><p>In a single-center retrospective study from Japan, 9 of 108 cases of gram-negative bacillary ocular infections were caused by <em>P. aeruginosa</em>; hospitalization and age ≥65 years were associated with drug-resistant <em>P. aeruginosa</em> infection [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Corneal and conjunctival infections</span></p><p class="headingAnchor" id="H42034467"><span class="h3">Clinical syndromes</span></p><p class="headingAnchor" id="H4"><span class="h4">Corneal infections</span><span class="headingEndMark"> — </span>Corneal infections due to <em>P. aeruginosa</em> usually result from minor trauma to the cornea. These infections may manifest as focal or diffuse inflammation of the cornea (keratitis) or as corneal ulcers if inflammation results in tissue loss and corneal erosion. </p><p><em>P. aeruginosa</em> is the most common cause of bacterial keratitis among contact lens wearers. Pseudomonas keratitis has been observed among patients using hydrophilic lenses and extended wear lenses, as the polymer matrix provides a suitable surface for <em>Pseudomonas</em> adherence. Extended lens wearing provides more time for lens surface coatings to accumulate, which promotes further bacterial adherence. Lens wear can then lead to bacterial accumulation on ocular surface by shielding the cornea from the immune components found in tears and from the wiping action of the eyelids. Although poor lens care practices such as use of contaminated solutions or tap water to clean lenses is commonly reported among affected individuals, <em>P. aeruginosa</em> can colonize contact lenses despite proper lens hygiene. </p><p>Traumatic epithelial defects also play a very important role in promoting keratitis secondary to contact lenses. Previous experimental models showed that corneal disease develops predominantly in corneas exposed to trauma, which can occur during lens insertion or removal [<a href="#rid3">3</a>]. Other predisposing conditions include use of topical steroids for other ocular diseases, contaminated ocular medications (eg, <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">artificial tears</a>), and prior ocular irradiation [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/6913.html" rel="external">"Complications of contact lenses", section on 'Infectious keratitis'</a>.)</p><p><em>P. aeruginosa</em> corneal ulcers usually start with a small lesion that rapidly spreads concentrically, in some cases leading to corneal perforation over a 48-hour period. Corneal ulcers can also be indolent, evolving slowly over days to weeks. Clinical findings include eye redness, decreased visual acuity, pain, eyelid swelling, photophobia, yellow infiltrates, and corneal epithelial defects visualized by <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> staining. Fever and other systemic manifestations are generally absent. Typically, there is a necrotic gray ulcer with adherent mucopurulent discharge and surrounding epithelial edema. <em>P. aeruginosa</em> corneal ulcers can result in secondary hypopyons or panophthalmitis.</p><p class="headingAnchor" id="H5"><span class="h4">Blepharoconjunctivitis</span><span class="headingEndMark"> — </span>Critically ill patients, neonates, or burn patients may develop unilateral or bilateral conjunctivitis due to <em>P. aeruginosa</em>. Conjunctival infection can occur with or without associated infection of the eyelids (blepharitis). Patients on mechanical ventilation are at increased risk for colonization of the eye with this organism, which can subsequently lead to conjunctivitis. Contamination of the conjunctiva with <em>P. aeruginosa</em> can occur during tracheal suctioning, when ventilator intubation tubes are disconnected, allowing eye inoculation from aerosols or direct contact with secretions [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of a corneal ulcer, keratitis, or conjunctivitis due to <em>P. aeruginosa</em> can be easily confirmed by obtaining scrapings from the bed of the ulcer or the conjunctiva for Gram stain and culture.</p><p class="headingAnchor" id="H7"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>The treatment of corneal and conjunctival infections usually consists of topical and systemic  (<a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">table 1</a>) antipseudomonal agents. In general, treatment should be based on available susceptibility results and continued until the clinical signs of active infection have resolved. Antibiotic selection for pseudomonal infections is detailed separately. (See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"</a>.)</p><p>In one series, subpalpebral lavage with antibiotics was used with good results [<a href="#rid5">5</a>]. Other adjunctive therapies that have been used in case reports or experimental models include hyperbaric oxygen and topical <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a> [<a href="#rid6">6-8</a>]. (See  <a class="medical medical_review" href="/z/d/html/6913.html" rel="external">"Complications of contact lenses", section on 'Infectious keratitis'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Endophthalmitis</span></p><p class="headingAnchor" id="H9"><span class="h3">Predisposing causes</span><span class="headingEndMark"> — </span>Five mechanisms can lead to <em>P. aeruginosa</em> endophthalmitis:</p><p class="bulletIndent1"><span class="glyph">●</span>Perforating corneal ulcers</p><p class="bulletIndent1"><span class="glyph">●</span>Penetrating ocular injuries</p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative complication of eye surgery</p><p class="bulletIndent1"><span class="glyph">●</span>Hematogenous spread</p><p class="bulletIndent1"><span class="glyph">●</span>Use of contaminated eye medications or solutions (eg, <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">artificial tears</a>) [<a href="#rid1">1</a>]</p><p></p><p>Unlike most forms of postoperative endophthalmitis, which occur when commensal colonizing ocular flora are inoculated into the eye, postsurgical <em>P. aeruginosa</em> endophthalmitis is more likely to result from exogenous sources, such as contaminated intraoperative air, irrigation fluids, intraocular lens, or even surgical equipment [<a href="#rid9">9,10</a>]. As an example, in an outbreak of post-operative <em>P. aeruginosa</em> endophthalmitis in an Indian hospital, polymerase chain reaction (PCR) analyses demonstrated that the main source of infection was a contaminated air-conditioning system [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/3418.html" rel="external">"Bacterial endophthalmitis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>The course of pseudomonal endophthalmitis is typically fulminant, developing over hours. Patients characteristically have intense ocular pain and decreased visual acuity. Findings of panophthalmitis, including conjunctivitis with chemosis, lid edema, and anterior uveitis, may also be present. </p><p>A retrospective review of 28 cases of <em>P. aeruginosa</em> endophthalmitis reported poor visual outcomes despite prompt treatment with intravitreal antibiotics to which the organisms were sensitive [<a href="#rid11">11</a>]. In this case series, 64 percent of affected eyes were either enucleated or eviscerated (ie, contents of the eye were removed, leaving only the sclera and attached ocular muscles).</p><p class="headingAnchor" id="H42034446"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>Endophthalmitis is diagnosed clinically by the presence of the characteristic symptoms and signs detailed above and the absence of a red reflex. The clinical diagnosis should be confirmed by aspiration of the anterior chamber or vitreous. Subsequent Gram stain and cultures will usually confirm the diagnosis either immediately or within 24 to 36 hours.</p><p class="headingAnchor" id="H11"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Therapy includes vitrectomy and intravitreal antibiotics. Treatment of bacterial endophthalmitis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3418.html" rel="external">"Bacterial endophthalmitis"</a>.) </p><p class="headingAnchor" id="H12"><span class="h1">EAR INFECTIONS</span><span class="headingEndMark"> — </span><em>P. aeruginosa</em> causes four types of ear infection:</p><p class="bulletIndent1"><span class="glyph">●</span>Simple otitis externa (or "swimmer's ear")</p><p class="bulletIndent1"><span class="glyph">●</span>Malignant external otitis</p><p class="bulletIndent1"><span class="glyph">●</span>Otitis media</p><p class="bulletIndent1"><span class="glyph">●</span>Perichondritis</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Otitis externa</span><span class="headingEndMark"> — </span><em>P. aeruginosa</em> is the most common cause of acute external otitis, accounting for more than 70 percent of cases in one series [<a href="#rid12">12,13</a>]. Otitis externa due to <em>P. aeruginosa</em> is common in swimmers and in residents of tropical or humid climates. In a prospective study of 99 cases of otitis externa, the peak incidence occurred in summer and early autumn months; exposure to water and previous use of ear drops and cotton-tipped applicators predisposed to infection [<a href="#rid14">14</a>]. In contrast to acute otitis externa, chronic otitis externa is generally caused by allergies or underlying inflammatory dermatologic conditions [<a href="#rid13">13</a>]. </p><p>Patients with otitis externa typically complain of itching and pain, worsened by traction on the pinna. Characteristically, there is a thick purulent discharge from the ear, and on examination, the external auditory canal is usually tender, edematous, and occluded with debris. The color or odor of the aural discharge is not useful in distinguishing between infection due to <em>P. aeruginosa</em> and otitis externa due to fungi or other organisms [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/6866.html" rel="external">"External otitis: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p>The treatment of external otitis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16516.html" rel="external">"External otitis: Treatment"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Skull base osteomyelitis</span><span class="headingEndMark"> — </span>In some patients, particularly elderly patients with diabetes mellitus, otitis externa may progress to a more severe and even life-threatening illness. Skull base osteomyelitis (also known as malignant external otitis) occurs when <em>P. aeruginosa</em> penetrates the epithelium of the external auditory canal and invades the underlying soft tissue, cartilage, and cortical bone. Infection may then occur in the soft tissue of the retromandibular and parotid spaces, the mastoid air cells, and the temporal bones. When the temporal bones become infected and necrotic, infection can spread to the base of the skull leading to inflammation and even necrosis of the ipsilateral seventh, ninth, tenth, eleventh, and twelfth cranial nerves.</p><p>Patients with skull base osteomyelitis usually present with pain and discharge from the affected ear. Hearing loss may or may not be present. On examination, the external auditory canal usually appears swollen and inflamed with a purulent discharge. Adjacent structures such as the pinna, periauricular and retromandibular areas, and the mastoid tip may also show signs of inflammation. The tympanic membrane, which may be either intact or perforated, is often hidden by the swelling and the granulation tissue. Cranial nerve palsies appear later in the course. Trismus may occur from infection of the temporomandibular joint.</p><p>Prompt diagnosis and treatment of this infection is essential. (See  <a class="medical medical_review" href="/z/d/html/3413.html" rel="external">"Malignant (necrotizing) external otitis"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Otitis media</span><span class="headingEndMark"> — </span><em>P. aeruginosa</em> is the most commonly isolated organism from the middle and external ears of patients with chronic suppurative otitis media. Otitis media due to <em>P. aeruginosa</em> can also occur in infants less than six weeks of age. The presence of this pathogen should be suspected when patients with otitis media fail to respond to usual antibiotic therapy. Neonates with otitis media due to <em>P. aeruginosa</em> often have misleading symptoms such as cough, rhinorrhea, diarrhea, and difficulty in feeding, whereas older children with <em>P. aeruginosa</em> ear infections usually have signs and symptoms typical of otitis media. (See  <a class="medical medical_review" href="/z/d/html/13590.html" rel="external">"Chronic suppurative otitis media (CSOM): Clinical features and diagnosis"</a>.)</p><p>The treatment of chronic suppurative otitis media is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/91002.html" rel="external">"Chronic suppurative otitis media (CSOM): Treatment, complications, and prevention"</a>.)</p><p>Acute otitis media can also occur in the presence of tympanostomy tubes [<a href="#rid15">15</a>]. <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">Piperacillin-tazobactam</a> coated tympanostomy tubes were noted to be resistant to <em>P. aeruginosa</em> biofilm formation in one study [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Perichondritis</span><span class="headingEndMark"> — </span><em>P. aeruginosa</em> perichondritis of the helix or tragus of the ear can occur after trauma, surgery, or burns. Cases have also been described after ear piercing [<a href="#rid17">17</a>] and acupuncture [<a href="#rid18">18</a>]. </p><p>In a systematic review of 29 case reports or small clusters of infectious complications following transcartilaginous ear piercing, 87 percent were caused by <em>P. aeruginosa</em> [<a href="#rid19">19</a>]. In one cluster of cases involving patients who underwent ear piercing at a commercial kiosk, <em>P. aeruginosa</em> was recovered from a disinfectant bottle and nearby sink; molecular subtyping confirmed a match with the isolates from infected patients [<a href="#rid20">20</a>]. The use of an open piercing gun as opposed to a sterile straight needle may predispose to an increased risk of infection secondary to shearing trauma of the perichondrium with the former methods [<a href="#rid21">21</a>]. Exposure of the wound to fresh water or hot tubs immediately after the procedure may additionally increase the risk of infection [<a href="#rid22">22</a>]. </p><p>Affected patients usually have a markedly swollen, red, and tender pinna. Infection may progress rapidly to produce necrosis of the cartilage. </p><p>Prompt therapy with antibiotics that have activity against <em>P. aeruginosa</em> is important  (<a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">table 1</a>), as perichondritis can result in permanent ear deformity [<a href="#rid23">23,24</a>]. In the systematic review of post-piercing infections noted above, delays of longer than five days before seeking treatment were associated with hospitalization, and perichondritis of the scapha (ie, the hollow part of the helix) versus the helix itself was associated with resultant ear deformity (100 versus 43 percent) [<a href="#rid19">19</a>]. </p><p>Oral <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> has been shown to be effective if the infecting strain is susceptible [<a href="#rid25">25</a>]. Infections may require prolonged antimicrobial therapy plus incision and drainage, as the cartilaginous portion of the ear has a poor blood supply. Abscesses, when present, should be drained promptly and cultured to both reduce the risk of pressure-induced cartilage damage and to provide a microbiological diagnosis and sensitivity results. (See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Antibiotics with antipseudomonal activity'</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">URINARY TRACT INFECTIONS</span></p><p class="headingAnchor" id="H18"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Urinary tract infections (UTIs) caused by <em>P. aeruginosa</em> are typically hospital-acquired. Community-acquired <em>P. aeruginosa</em> is less common and generally occurs in patients with some predisposing factor. </p><p class="headingAnchor" id="H129695240"><span class="h3">Hospital acquired</span><span class="headingEndMark"> — </span><em>P. aeruginosa</em> is the third most common pathogen to cause hospital-acquired UTIs, after <em>Escherichia coli</em> and <em>Enterococcus</em> spp. Most such UTIs occur in patients with impaired host defenses and in those who have had recent urinary tract instrumentation and/or chronic indwelling urinary catheters. (See  <a class="medical medical_review" href="/z/d/html/8054.html" rel="external">"Catheter-associated urinary tract infection in adults"</a>.)</p><p>Most strains of<em> P. aeruginosa</em> causing catheter-associated UTIs produce biofilms. A microbiologic study of <em>P. aeruginosa</em> isolates recovered from patients with indwelling urinary catheters found 20 of 26 (77 percent) were biofilm producers [<a href="#rid26">26</a>]. The majority of the isolates were multidrug resistant (69 percent); <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> resistance correlated with increased biofilm production. The association of gentamicin resistance and biofilm production could partly explain the increased prevalence of gentamicin-resistant infections encountered in this clinical setting.</p><p>Other identified risk factors for hospital-acquired <em>P. aeruginosa </em>UTI include male sex, longer hospitalization prior to UTI, and prior use of penicillins, third-generation cephalosporins, carbapenems, aminoglycosides, and <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid27">27</a>]. </p><p>Other outbreaks of <em>P. aeruginosa</em> infection of the urinary tract have also occurred from contaminated urologic equipment or facilities including:</p><p class="bulletIndent1"><span class="glyph">●</span>Urodynamic equipment [<a href="#rid28">28,29</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>A cystoscopy room via an unsealed drain [<a href="#rid30">30</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>A urology unit with a contaminated sink, scope, and bedside table [<a href="#rid31">31</a>]</p><p></p><p class="headingAnchor" id="H129695246"><span class="h3">Community-acquired</span><span class="headingEndMark"> — </span>Community-acquired UTIs due to <em>P. aeruginosa</em> usually develop in patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary tract obstruction</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic prostatitis</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged courses of antibiotic therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent infections</p><p></p><p>In women, colonization of the vaginal introitus may rarely serve as a reservoir for community-acquired <em>P. aeruginosa</em> UTIs [<a href="#rid32">32</a>]. <em>P. aeruginosa</em> rarely causes UTIs in otherwise healthy school children. </p><p class="headingAnchor" id="H19"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>The clinical manifestations of <em>P. aeruginosa</em> UTIs are similar to infections caused by other pathogens. Typical signs and symptoms include dysuria, frequency, urgency, suprapubic pain, and/or hematuria with cystitis and fever, chills, and flank pain in addition to patients with pyelonephritis. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Clinical manifestations'</a>.)</p><p>However, certain features may be more common in patients with UTIs due to <em>P. aeruginosa</em>. For example, ulcerations in the mucosa of the bladder, ureters, and renal pelvis may rarely occur in severe infections due to <em>P. aeruginosa</em>. When ulcerations develop, obstruction or bleeding can result. Also, patients with UTIs due to <em>P. aeruginosa</em> may rarely have green urine. However, green urine has many other causes, including foods containing coloring agents and various medications [<a href="#rid33">33-35</a>]. </p><p>Additionally, involvement of the urinary tract may occur from either ascending infection or hematogenous spread from a distant source of primary infection. In cases of hematogenous spread, renal infarcts may occur from bacterial invasion of medium and small-sized blood vessels.</p><p class="headingAnchor" id="H129695418"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of <em>P. aeruginosa</em> UTI is similar to that for UTIs caused by other organisms. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Diagnostic approach'</a>.)</p><p>For patients with a chronic indwelling bladder catheter, the isolation of <em>P. aeruginosa</em> from the urine is not diagnostic of a UTI, since bacteriuria and even pyuria in the absence of overt infection are common in such settings. The presence of consistent symptoms should determine whether infection is present and antibiotics should be administered.</p><p class="headingAnchor" id="H20"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The management of <em>P. aeruginosa</em> UTI (ie, bacteriuria accompanied by symptoms consistent with UTI) involves antibiotic administration as well as correction of obstruction and removal of an indwelling catheter, if present. When <em>P. aeruginosa</em> UTI occurs in a patient with a chronic indwelling bladder catheter, eradication of the organism is usually impossible without catheter removal. If needed, the catheter should be replaced at the outset of antibiotic therapy. (See  <a class="medical medical_review" href="/z/d/html/8054.html" rel="external">"Catheter-associated urinary tract infection in adults", section on 'Treatment'</a>.) </p><p>The approach to empiric antimicrobial treatment of acute simple cystitis and acute complicated UTI is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">"Acute simple cystitis in adult and adolescent females"</a> and  <a class="medical medical_review" href="/z/d/html/8059.html" rel="external">"Acute simple cystitis in adult and adolescent males"</a> and  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a>.)</p><p>Once <em>P. aeruginosa</em> has been identified as the cause, the antimicrobial regimen can be tailored to the susceptibility of the isolate. Any antipseudomonal antibiotic to which the isolate is susceptible should be effective  (<a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with acute simple cystitis due to <em>P. aeruginosa</em>, <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a> may be an active option depending on regional susceptibility [<a href="#rid36">36,37</a>]. Fosfomycin susceptibilities may need to be specifically requested. However, emergent fosfomycin resistance during treatment is a potential concern based on a simulation study [<a href="#rid38">38</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An oral fluoroquinolone, such as <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> can be used for acute simple cystitis and for acute complicated <em>P. aeruginosa</em> UTI provided the isolate is susceptible and the patient is a suitable candidate for oral therapy. </p><p></p><p>Other options for antipseudomonal therapy are parenteral  (<a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">table 1</a>). Resistant isolates may only be susceptible to novel antimicrobial agents, such as <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> [<a href="#rid39">39</a>], <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> [<a href="#rid40">40</a>], and <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">plazomicin</a> [<a href="#rid41">41</a>]. Options for resistant <em>P. aeruginosa</em> isolates are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Antibiotics with antipseudomonal activity'</a>.)</p><p>The duration of treatment for <em>P. aeruginosa</em> UTI is the same as for UTIs caused by other organisms. (See  <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">"Acute simple cystitis in adult and adolescent females", section on 'Alternative antimicrobial options'</a> and  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Duration'</a>.)</p><p>three to five days for simple cystitis, two to three weeks for pyelonephritis, and longer pending clinical resolution for intrarenal and perinephric abscesses. When cystitis is complicated by sepsis or bacteremia, the optimal duration is uncertain. In the absence of urinary obstruction, foreign bodies (such as stones or catheters), or abscess, antibiotic therapy can be discontinued after clinical and laboratory signs and symptoms of infection have resolved. This generally takes longer than five days.</p><p>The value of chronic suppressive therapy to prevent recurrence following a curative course of antibiotics for <em>P. aeruginosa</em> UTI is often limited by the lack of effective oral agents with significant antipseudomonal activity. Although <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> generally has good in vitro activity against <em>P. aeruginosa</em>, this agent often rapidly induces the development of resistance when used for suppression. <a class="drug drug_general" data-topicid="9626" href="/z/d/drug information/9626.html" rel="external">Methenamine</a> salt administered in combination with ascorbic acid has been used by some for chronic suppression of UTI due to drug resistant organisms, but we do not endorse this practice since the long-term efficacy of this agent is poor [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/8053.html" rel="external">"Recurrent simple cystitis in women", section on 'Methenamine'</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">GASTROINTESTINAL INFECTIONS</span><span class="headingEndMark"> — </span>Although uncommon, particular gastrointestinal tract infections with <em>P. aeruginosa</em> have been described.</p><p class="headingAnchor" id="H129695557"><span class="h2">Clinical syndromes</span></p><p class="headingAnchor" id="H22"><span class="h2">Post ERCP</span><span class="headingEndMark"> — </span><em>P. aeruginosa</em> cholangitis and bacteremia following endoscopic retrograde cholangiopancreatography (ERCP) have been described, with the same strain or serotype found in the blood of patients and the implicated endoscope [<a href="#rid43">43-46</a>]. The source of these infections has been traced to inadequate decontamination or cleaning of the endoscope, contamination with nonsterile rinse water following decontamination, or inadequate drying of the endoscope.</p><p>Septic complications following ERCP are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/641.html" rel="external">"Infectious adverse events related to endoscopic retrograde cholangiopancreatography (ERCP)"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Typhlitis</span><span class="headingEndMark"> — </span>Typhlitis, or neutropenic enterocolitis of the cecum or surrounding gut, is most commonly seen in patients with chemotherapy-induced neutropenia. Although such infections are polymicrobial, <em>P. aeruginosa</em> has been detected from the blood in some patients at the time of presentation with this syndrome [<a href="#rid47">47,48</a>]. </p><p>Typhlitis has been most commonly described in children with leukemia but may also occur in adults with leukemia and in patients with neutropenia from chemotherapy used for treatment of solid tumors. </p><p>Patients with typhlitis present with the sudden onset of fever with abdominal pain (particularly in the right-lower quadrant) and distention. Because diarrhea and fever are common toxicities associated with high dose chemotherapy, it is likely that many cases of typhlitis go unrecognized. Computed tomography and/or ultrasonography should be performed in all neutropenic patients with right-lower-quadrant signs to permit prompt diagnosis and treatment [<a href="#rid47">47</a>]. Typhlitis should be suspected in any immunocompromised patient presenting with right lower quadrant pain and compatible radiographic findings. </p><p>Most patients can be treated conservatively with intravenous fluids and antibiotics, although surgery may be necessary if complications arise [<a href="#rid49">49</a>]. Antibiotics with activity against <em>P. aeruginosa</em> are discussed elsewhere  (<a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Antibiotics with antipseudomonal activity'</a>.)</p><p>Typhlitis is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/2690.html" rel="external">"Neutropenic enterocolitis (typhlitis)"</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Enteritis due to P. aeruginosa (Shanghai fever)</span><span class="headingEndMark"> — </span>Enteritis due to <em>P. aeruginosa</em> (Shanghai fever) may mimic the clinical features of typhoid fever and produce fever, splenomegaly, diarrhea, and even "rose spots" [<a href="#rid50">50</a>]. Cases have mainly been reported in infants and children from Taiwan and China. The clinical course can be severe. In a series of 27 children from Taiwan with febrile diarrhea, sepsis, and <em>P. aeruginosa</em> isolated from a clinical specimen (blood or other sample), 23 had necrotizing enteritis, nine had bowel perforation requiring surgery, seven had seizures in the setting of hyponatremia, and two had meningitis [<a href="#rid51">51</a>].</p><p>Given the few reported cases, treatment of this entity has not been extensively studied. The general principles of antipseudomonal therapy are likely to apply. These and specific antibiotics with activity against <em>P. aeruginosa</em> are discussed elsewhere  (<a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">CENTRAL NERVOUS SYSTEM INFECTIONS</span><span class="headingEndMark"> — </span>Meningitis or suppurative brain abscesses due to <em>P. aeruginosa</em> are rare. Most patients with central nervous system (CNS) infections caused by <em>P. aeruginosa</em> have serious underlying diseases or have had recent trauma, neurosurgical procedures, or burns [<a href="#rid52">52-55</a>]. </p><p>In a retrospective case series, <em>P. aeruginosa</em> was the second most common etiologic agent in uremic hemodialysis patients with bacterial meningitis [<a href="#rid52">52</a>]. In a study of 544 episodes of spontaneous acute bacterial meningitis, gram-negative bacilli were identified as the causative agent in 40 (7 percent), and <em>P. aeruginosa</em> was the second most common gram-negative pathogen [<a href="#rid53">53</a>]. Clinical factors independently associated with <em>P. aeruginosa</em> included advanced age, history of cancer, hospital-acquired infection, urinary tract infection as a distant focus of infection, absence of rash, hypotension, and a high cerebrospinal fluid white-cell count. The in-hospital mortality rate was 53 percent.</p><p>Clinical features and diagnosis of <em>P. aeruginosa</em> CNS infections are similar to those for infections caused by other gram-negative pathogens. (See  <a class="medical medical_review" href="/z/d/html/1302.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p>Empiric therapy of gram-negative bacillary meningitis is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis", section on 'Systemic antimicrobial therapy'</a>.)</p><p>Once <em>P. aeruginosa</em> is identified as the causative agent and susceptibility testing returns, we use a single antipseudomonal agent to which the isolate is susceptible and that has good CSF penetration, preferably <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>. For CNS infections due to multidrug-resistant isolates, <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> may be an option [<a href="#rid56">56</a>]. There is no clear evidence that combination therapy offers additional benefit in directed therapy of <em>P. aeruginosa</em> infections. (See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Role of combination antimicrobial therapy'</a>.) </p><p>We treat for at least 21 days, although therapy should be individualized. Repeat CSF analysis and culture should confirm clearance of the organism. Treatment of drug resistant organisms should be done in consultation with an expert in treating such infections and may include alternative agents such as <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> and local (eg, intrathecal) therapy. (See  <a class="medical medical_review" href="/z/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis", section on 'Intrathecal and intraventricular therapy'</a>.) </p><p class="headingAnchor" id="H24928232"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15736.html" rel="external">"Patient education: Outer ear infection (The Basics)"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3998.html" rel="external">"Patient education: External otitis (including swimmer's ear) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H302538208"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical significance of </strong><strong><em>Pseudomonas aeruginosa</em></strong> – <em>P. aeruginosa </em>can cause severe hospital-acquired infections (especially in immunocompromised hosts), is often antibiotic resistant, and is often associated with a high mortality rate. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye infections</strong> – <em>P. aeruginosa </em>can cause both minor and vision-threatening infections of the eye. These infections include dacryocystitis, blepharoconjunctivitis, and orbital cellulitis. The pathogen can also be directly introduced into the cornea, anterior chamber, or vitreous via trauma or surgery. <em>P. aeruginosa </em>has been implicated in some cases of ophthalmia neonatorum and scleral abscesses. Hematogenous infection of the vitreous occurs rarely in patients with <em>P. aeruginosa </em>bacteremia. (See <a class="local">'Eye infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Corneal infections due to </strong><strong><em>P. aeruginosa</em></strong> – These usually result from minor trauma to the cornea and are frequently associated with contact lens use. Clinical signs are usually localized to the eye; fever and other systemic manifestations are generally absent. Diagnosis is made by Gram stain and culture of corneal scrapings. Treatment usually consists of topical and systemic antipseudomonal agents. (See <a class="local">'Corneal and conjunctival infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endophthalmitis</strong> – Endophthalmitis can occur in the setting of perforated corneal ulcers, following penetrating ocular injuries, following eye surgery, and from hematogenous spread. The course of pseudomonal endophthalmitis is typically fulminant, developing over hours. Patients virtually always have intense ocular pain accompanied by decreased visual acuity. The diagnosis is made clinically and confirmed with vitreal cultures. Therapy of <em>P. aeruginosa</em> endophthalmitis frequently includes vitrectomy and intravitreal antibiotics. (See <a class="local">'Endophthalmitis'</a> above and  <a class="medical medical_review" href="/z/d/html/3418.html" rel="external">"Bacterial endophthalmitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ear infections</strong> – <em>P. aeruginosa</em> causes four types of ear infection: simple otitis externa (ie, "swimmer's ear"), malignant external otitis, otitis media, and perichondritis. (See <a class="local">'Ear infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Otitis externa</strong> – <em>P. aeruginosa</em> is the most common cause of external otitis, accounting for more than 70 percent of all cases. Otitis externa due to <em>P. aeruginosa</em> is common in swimmers and in residents of tropical or humid climates. (See <a class="local">'Otitis externa'</a> above.)</p><p></p><p class="bulletIndent2">In some patients, particularly elderly patients with diabetes mellitus, otitis externa may progress to a more severe and even life-threatening illness. Skull base osteomyelitis (also known as malignant external otitis) occurs when <em>P. aeruginosa</em> penetrates the epithelium of the external auditory canal and invades the underlying soft tissue, cartilage, and cortical bone. (See <a class="local">'Skull base osteomyelitis'</a> above and  <a class="medical medical_review" href="/z/d/html/3413.html" rel="external">"Malignant (necrotizing) external otitis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Otitis media</strong> – <em>P. aeruginosa</em> is the most commonly isolated organism from the middle and external ears of patients with chronic suppurative otitis media. Otitis media due to <em>P. aeruginosa</em> can also occur in infants less than six weeks of age. The presence of this pathogen should be suspected when patients with otitis media fail to respond to usual antibiotic therapy. (See <a class="local">'Otitis media'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other types of infections</strong> – Other sites of infection discussed in this topic include urinary tract infections (UTIs), gastrointestinal infections, and central nervous infections.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>UTIs</strong> – UTIs caused by <em>P. aeruginosa</em> are typically hospital-acquired or associated with urinary tract obstruction, chronic prostatitis, prolonged courses of antibiotic therapy, or recurrent infections. Management involves antibiotic administration  (<a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">table 1</a>) as well as surgically correcting any obstruction and removing an indwelling catheter. (See <a class="local">'Urinary tract infections'</a> above and  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal infections</strong> – <em>P. aeruginosa</em> can cause bacteremia following endoscopic retrograde cholangiopancreatography and typhlitis in patients with chemotherapy-induced neutropenia. (See <a class="local">'Gastrointestinal infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Central nervous system infections</strong> – Meningitis or suppurative brain abscesses due to <em>P. aeruginosa</em> can occur, especially in patients with serious underlying diseases or recent trauma or neurosurgical procedures. (See <a class="local">'Central nervous system infections'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Health Alert Network. Outbreak of extensively drug-resistant Pseudomonas aeruginosa associated with artificial tears. Centers for Disease Control and Prevention. Feb 1, 2023. Available at: https://emergency.cdc.gov/han/2023/han00485.asp (Accessed on February 02, 2023).</li><li><a class="nounderline abstract_t">Sato KI. Prevalence and Possible Predictors of Drug-Resistant Pseudomonas aeruginosa in External Ocular Infections: A Single-Center, Retrospective, Cross-Sectional Study. Cureus 2020; 12:e8082.</a></li><li><a class="nounderline abstract_t">Stern GA. Pseudomonas keratitis and contact lens wear: the lens/eye is at fault. Cornea 1990; 9 Suppl 1:S36.</a></li><li><a class="nounderline abstract_t">Smulders C, Brink H, Wanten G, et al. Conjunctival and corneal colonization by Pseudomonas aeruginosa in mechanically ventilated patients. A prospective study. Neth J Med 1999; 55:106.</a></li><li><a class="nounderline abstract_t">Meallet MA. Subpalpebral lavage antibiotic treatment for severe infectious scleritis and keratitis. Cornea 2006; 25:159.</a></li><li><a class="nounderline abstract_t">Chong R, Ayer CJ, Francis IC, et al. Adjunctive hyperbaric oxygen in pseudomonas keratitis. Br J Ophthalmol 2007; 91:560.</a></li><li><a class="nounderline abstract_t">McCormick C, Caballero A, Tang A, et al. Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis. Curr Med Res Opin 2008; 24:1569.</a></li><li><a class="nounderline abstract_t">Bu P, Riske PS, Zaya NE, et al. A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. J Ocul Pharmacol Ther 2007; 23:213.</a></li><li><a class="nounderline abstract_t">Cruciani M, Malena M, Amalfitano G, et al. Molecular epidemiology in a cluster of cases of postoperative Pseudomonas aeruginosa endophthalmitis. Clin Infect Dis 1998; 26:330.</a></li><li><a class="nounderline abstract_t">Pinna A, Usai D, Sechi LA, et al. An outbreak of post-cataract surgery endophthalmitis caused by Pseudomonas aeruginosa. Ophthalmology 2009; 116:2321.</a></li><li><a class="nounderline abstract_t">Eifrig CW, Scott IU, Flynn HW Jr, Miller D. Endophthalmitis caused by Pseudomonas aeruginosa. Ophthalmology 2003; 110:1714.</a></li><li><a class="nounderline abstract_t">Clark WB, Brook I, Bianki D, Thompson DH. Microbiology of otitis externa. Otolaryngol Head Neck Surg 1997; 116:23.</a></li><li><a class="nounderline abstract_t">Schaefer P, Baugh RF. Acute otitis externa: an update. Am Fam Physician 2012; 86:1055.</a></li><li><a class="nounderline abstract_t">Hawke M, Wong J, Krajden S. Clinical and microbiological features of otitis externa. J Otolaryngol 1984; 13:289.</a></li><li><a class="nounderline abstract_t">Roland PS, Parry DA, Stroman DW. Microbiology of acute otitis media with tympanostomy tubes. Otolaryngol Head Neck Surg 2005; 133:585.</a></li><li><a class="nounderline abstract_t">Jang CH, Park H, Cho YB, et al. The use of piperacillin-tazobactam coated tympanostomy tubes against ciprofloxacin-resistant Pseudomonas biofilm formation: an in vitro study. Int J Pediatr Otorhinolaryngol 2009; 73:295.</a></li><li><a class="nounderline abstract_t">Cumberworth VL, Hogarth TB. Hazards of ear-piercing procedures which traverse cartilage: a report of Pseudomonas perichondritis and review of other complications. Br J Clin Pract 1990; 44:512.</a></li><li><a class="nounderline abstract_t">Warwick-Brown NP, Richards AE. Perichondritis of the ear following acupuncture. J Laryngol Otol 1986; 100:1177.</a></li><li><a class="nounderline abstract_t">Sosin M, Weissler JM, Pulcrano M, Rodriguez ED. Transcartilaginous ear piercing and infectious complications: a systematic review and critical analysis of outcomes. Laryngoscope 2015; 125:1827.</a></li><li><a class="nounderline abstract_t">Keene WE, Markum AC, Samadpour M. Outbreak of Pseudomonas aeruginosa infections caused by commercial piercing of upper ear cartilage. JAMA 2004; 291:981.</a></li><li><a class="nounderline abstract_t">Lee TC, Gold WL. Necrotizing Pseudomonas chondritis after piercing of the upper ear. CMAJ 2011; 183:819.</a></li><li><a class="nounderline abstract_t">Rowshan HH, Keith K, Baur D, Skidmore P. Pseudomonas aeruginosa infection of the auricular cartilage caused by "high ear piercing": a case report and review of the literature. J Oral Maxillofac Surg 2008; 66:543.</a></li><li><a class="nounderline abstract_t">Liu ZW, Chokkalingam P. Piercing associated perichondritis of the pinna: are we treating it correctly? J Laryngol Otol 2013; 127:505.</a></li><li><a class="nounderline abstract_t">Davidi E, Paz A, Duchman H, et al. Perichondritis of the auricle: analysis of 114 cases. Isr Med Assoc J 2011; 13:21.</a></li><li><a class="nounderline abstract_t">Noel SB, Scallan P, Meadors MC, et al. Treatment of Pseudomonas aeruginosa auricular perichondritis with oral ciprofloxacin. J Dermatol Surg Oncol 1989; 15:633.</a></li><li><a class="nounderline abstract_t">Suman E, Varghese S, Jose J. Gentamicin resistance in biofilm producing Pseudomonas aeruginosa causing catheter associated urinary tract infections. Indian J Med Sci 2005; 59:214.</a></li><li><a class="nounderline abstract_t">Djordjevic Z, Folic MM, Zivic Z, et al. Nosocomial urinary tract infections caused by Pseudomonas aeruginosa and Acinetobacter species: sensitivity to antibiotics and risk factors. Am J Infect Control 2013; 41:1182.</a></li><li><a class="nounderline abstract_t">Yardy GW, Cox RA. An outbreak of Pseudomonas aeruginosa infection associated with contaminated urodynamic equipment. J Hosp Infect 2001; 47:60.</a></li><li><a class="nounderline abstract_t">Bilavsky E, Pfeffer I, Tarabeia J, et al. Outbreak of multidrug-resistant Pseudomonas aeruginosa infection following urodynamic studies traced to contaminated transducer. J Hosp Infect 2013; 83:344.</a></li><li><a class="nounderline abstract_t">Peña C, Dominguez MA, Pujol M, et al. An outbreak of carbapenem-resistant Pseudomonas aeruginosa in a urology ward. Clin Microbiol Infect 2003; 9:938.</a></li><li><a class="nounderline abstract_t">Boutiba-Ben Boubaker I, Boukadida J, Triki O, et al. [Outbreak of nosocomial urinary tract infections due to a multidrug resistant Pseudomonas aeruginosa]. Pathol Biol (Paris) 2003; 51:147.</a></li><li class="breakAll">Stamey, TA. Rinary infections. Williams &amp;Wilkins, Baltimore 1972. p.279.</li><li><a class="nounderline abstract_t">Carpenito G, Kurtz I. Green urine in a critically ill patient. Am J Kidney Dis 2002; 39:E20.</a></li><li><a class="nounderline abstract_t">Leclercq P, Loly C, Delanaye P, et al. Green urine. Lancet 2009; 373:1462.</a></li><li><a class="nounderline abstract_t">Boshkovska Spaseski M, Spaseski D. Green Urine. N Engl J Med 2020; 383:e128.</a></li><li><a class="nounderline abstract_t">Batra P, Abrol AK, Gupta S, et al. Susceptibility pattern of oral antimicrobials in uncomplicated UTI: Does fosfomycin still stand effective? J Family Med Prim Care 2020; 9:850.</a></li><li><a class="nounderline abstract_t">Maraki S, Samonis G, Rafailidis PI, et al. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 2009; 53:4508.</a></li><li><a class="nounderline abstract_t">Abbott IJ, van Gorp E, Wijma RA, et al. Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model. J Antimicrob Chemother 2020; 75:1879.</a></li><li><a class="nounderline abstract_t">Gallagher JC, Satlin MJ, Elabor A, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study. Open Forum Infect Dis 2018; 5:ofy280.</a></li><li><a class="nounderline abstract_t">Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 16:661.</a></li><li><a class="nounderline abstract_t">Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med 2019; 380:729.</a></li><li><a class="nounderline abstract_t">Banovac K, Wade N, Gonzalez F, et al. Decreased incidence of urinary tract infections in patients with spinal cord injury: effect of methenamine. J Am Paraplegia Soc 1991; 14:52.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control (CDC). Nosocomial infection and pseudoinfection from contaminated endoscopes and bronchoscopes--Wisconsin and Missouri. MMWR Morb Mortal Wkly Rep 1991; 40:675.</a></li><li><a class="nounderline abstract_t">Spach DH, Silverstein FE, Stamm WE. Transmission of infection by gastrointestinal endoscopy and bronchoscopy. Ann Intern Med 1993; 118:117.</a></li><li><a class="nounderline abstract_t">Fraser TG, Reiner S, Malczynski M, et al. Multidrug-resistant Pseudomonas aeruginosa cholangitis after endoscopic retrograde cholangiopancreatography: failure of routine endoscope cultures to prevent an outbreak. Infect Control Hosp Epidemiol 2004; 25:856.</a></li><li><a class="nounderline abstract_t">McCafferty CE, Aghajani MJ, Abi-Hanna D, et al. An update on gastrointestinal endoscopy-associated infections and their contributing factors. Ann Clin Microbiol Antimicrob 2018; 17:36.</a></li><li><a class="nounderline abstract_t">Sloas MM, Flynn PM, Kaste SC, Patrick CC. Typhlitis in children with cancer: a 30-year experience. Clin Infect Dis 1993; 17:484.</a></li><li><a class="nounderline abstract_t">Katz JA, Wagner ML, Gresik MV, et al. Typhlitis. An 18-year experience and postmortem review. Cancer 1990; 65:1041.</a></li><li><a class="nounderline abstract_t">Urbach DR, Rotstein OD. Typhlitis. Can J Surg 1999; 42:415.</a></li><li><a class="nounderline abstract_t">Altucci P, Abbate GF, Leonessa V, Alagia I. [Classification of acute bacterial enteropathies]. Minerva Med 1977; 68:2575.</a></li><li><a class="nounderline abstract_t">Chuang CH, Wang YH, Chang HJ, et al. Shanghai fever: a distinct Pseudomonas aeruginosa enteric disease. Gut 2014; 63:736.</a></li><li><a class="nounderline abstract_t">Cheng BC, Chang WN, Lu CH, et al. Bacterial meningitis in hemodialyzed patients. J Nephrol 2004; 17:236.</a></li><li><a class="nounderline abstract_t">Pomar V, Benito N, López-Contreras J, et al. Spontaneous gram-negative bacillary meningitis in adult patients: characteristics and outcome. BMC Infect Dis 2013; 13:451.</a></li><li><a class="nounderline abstract_t">Pollock S. Understanding liability insurance: the "tail" termination. Dent Manage 1989; 29:34.</a></li><li><a class="nounderline abstract_t">Segal N, Polcz VE, McKean JA, et al. Pseudomonal Meningoencephalitis With Ventriculitis Secondary to Bacteremia in a Burn Patient: A Novel Case. J Burn Care Res 2021; 42:832.</a></li><li><a class="nounderline abstract_t">McCreary EK, Byers KE, Fernandes C, et al. Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Pseudomonas aeruginosa Meningitis. Open Forum Infect Dis 2020; 7:ofaa549.</a></li></ol></div><div id="topicVersionRevision">Topic 3148 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://emergency.cdc.gov/han/2023/han00485.asp" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Health Alert Network. Outbreak of extensively drug-resistant Pseudomonas aeruginosa associated with artificial tears. Centers for Disease Control and Prevention. Feb 1, 2023. Available at: https://emergency.cdc.gov/han/2023/han00485.asp (Accessed on February 02, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32542137" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence and Possible Predictors of Drug-Resistant Pseudomonas aeruginosa in External Ocular Infections: A Single-Center, Retrospective, Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189678" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pseudomonas keratitis and contact lens wear: the lens/eye is at fault.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10509068" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Conjunctival and corneal colonization by Pseudomonas aeruginosa in mechanically ventilated patients. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371774" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Subpalpebral lavage antibiotic treatment for severe infectious scleritis and keratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17372345" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adjunctive hyperbaric oxygen in pseudomonas keratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18423106" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17593004" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9502450" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Molecular epidemiology in a cluster of cases of postoperative Pseudomonas aeruginosa endophthalmitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19815282" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An outbreak of post-cataract surgery endophthalmitis caused by Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13129867" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Endophthalmitis caused by Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9018252" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Microbiology of otitis externa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23198673" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute otitis externa: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6544842" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical and microbiological features of otitis externa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16213934" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Microbiology of acute otitis media with tympanostomy tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19095310" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The use of piperacillin-tazobactam coated tympanostomy tubes against ciprofloxacin-resistant Pseudomonas biofilm formation: an in vitro study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2282313" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hazards of ear-piercing procedures which traverse cartilage: a report of Pseudomonas perichondritis and review of other complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3772244" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Perichondritis of the ear following acupuncture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25825232" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Transcartilaginous ear piercing and infectious complications: a systematic review and critical analysis of outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14982914" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Outbreak of Pseudomonas aeruginosa infections caused by commercial piercing of upper ear cartilage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115677" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Necrotizing Pseudomonas chondritis after piercing of the upper ear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280391" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pseudomonas aeruginosa infection of the auricular cartilage caused by "high ear piercing": a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23442437" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Piercing associated perichondritis of the pinna: are we treating it correctly?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21446231" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Perichondritis of the auricle: analysis of 114 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2723226" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Treatment of Pseudomonas aeruginosa auricular perichondritis with oral ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985732" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gentamicin resistance in biofilm producing Pseudomonas aeruginosa causing catheter associated urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23726656" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nosocomial urinary tract infections caused by Pseudomonas aeruginosa and Acinetobacter species: sensitivity to antibiotics and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11161900" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : An outbreak of Pseudomonas aeruginosa infection associated with contaminated urodynamic equipment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23419597" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Outbreak of multidrug-resistant Pseudomonas aeruginosa infection following urodynamic studies traced to contaminated transducer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616682" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : An outbreak of carbapenem-resistant Pseudomonas aeruginosa in a urology ward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12781795" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : [Outbreak of nosocomial urinary tract infections due to a multidrug resistant Pseudomonas aeruginosa].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12781795" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : [Outbreak of nosocomial urinary tract infections due to a multidrug resistant Pseudomonas aeruginosa].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920362" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Green urine in a critically ill patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19394536" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Green urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33264548" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Green Urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32318433" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Susceptibility pattern of oral antimicrobials in uncomplicated UTI: Does fosfomycin still stand effective?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687248" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Susceptibility of urinary tract bacteria to fosfomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32361749" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30488041" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27107460" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30786187" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Once-Daily Plazomicin for Complicated Urinary Tract Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2051157" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Decreased incidence of urinary tract infections in patients with spinal cord injury: effect of methenamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1910146" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Nosocomial infection and pseudoinfection from contaminated endoscopes and bronchoscopes--Wisconsin and Missouri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416308" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Transmission of infection by gastrointestinal endoscopy and bronchoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15518029" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Multidrug-resistant Pseudomonas aeruginosa cholangitis after endoscopic retrograde cholangiopancreatography: failure of routine endoscope cultures to prevent an outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30314500" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : An update on gastrointestinal endoscopy-associated infections and their contributing factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8218694" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Typhlitis in children with cancer: a 30-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2404562" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Typhlitis. An 18-year experience and postmortem review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10593241" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Typhlitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/896078" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : [Classification of acute bacterial enteropathies].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23943780" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Shanghai fever: a distinct Pseudomonas aeruginosa enteric disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15293523" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Bacterial meningitis in hemodialyzed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24079517" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Spontaneous gram-negative bacillary meningitis in adult patients: characteristics and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2599187" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Understanding liability insurance: the "tail" termination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33484564" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pseudomonal Meningoencephalitis With Ventriculitis Secondary to Bacteremia in a Burn Patient: A Novel Case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33409327" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Pseudomonas aeruginosa Meningitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
